Acute/Chronic Renal Failure
Research by Perin et al. indicated that Amniotic Fluid Stem Cells (AF-SCs) were able to be induced to a renal fate in an ex vivo system. These researchers found that injection of AF-SCs into damaged kidney provides a protective effect ameliorating acute tubular necrosis (ATN) in the acute phase. They concluded that the cells could represent a novel source of stem cells that may function to modulate the kidney immune milieu in renal failure caused by ATN (83 ).
It was determined by the National Academy of Sciences that repeated IV drips or direct Interventional application of Amniotic Fluid Stem Cells to Kidney will improve kidney function. The use of hAFSCs to treat renal disease shows promise toward restoration of normal kidney functions. Hauser et al. have shown that intravenous infusion of hAFSCs resulted in more rapid recovery of renal function compared to infusion of BM-MSCs. The authors of the study suggest that a range of cytokine and growth factors produced by hAFSCs gives them the advantage in renal regeneration. In addition, the preconditioning effects of hAFSCs were evaluated for renal function recovery.
Hauser PV, De Fazio R, Bruno S, Sdei S, Grange C, Bussolati B, et al. Stem cells derived from human amniotic fluid contribute to acute kidney injury recovery. Am J Pathol. 2010;177:2011–2021.
This good news is perhaps to hard to believe, but the publication are available to find therapies that are working to help regrow kidney tubules, reduce inflammation, return function and reduce dialysis visits, these are worthwhile proven results.